RedHill Biopharma Files 6-K Report
Ticker: RDHL · Form: 6-K · Filed: Apr 8, 2025 · CIK: 1553846
| Field | Detail |
|---|---|
| Company | Redhill Biopharma Ltd. (RDHL) |
| Form Type | 6-K |
| Filed Date | Apr 8, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, foreign-private-issuer, registration-statement
Related Tickers: RHBP
TL;DR
RHBP filed a 6-K, mostly procedural stuff incorporated into old S-8s. No new material info.
AI Summary
RedHill Biopharma Ltd. filed a Form 6-K on April 8, 2025, to report its status as a foreign private issuer. This filing is incorporated by reference into several of the company's previous S-8 registration statements, which relate to employee stock plans.
Why It Matters
This filing serves as an update for investors regarding RedHill Biopharma's regulatory status and its ongoing incorporation of information into existing registration statements.
Risk Assessment
Risk Level: low — The filing is a routine procedural update and does not contain new financial or operational information that would significantly impact the company's risk profile.
Key Players & Entities
- RedHill Biopharma Ltd. (company) — Registrant
- April 8, 2025 (date) — Filing Date
- Form 6-K (document) — Filing Type
- Form S-8 (document) — Incorporated Document
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose of this Form 6-K filing is to report RedHill Biopharma Ltd.'s status as a foreign private issuer and to incorporate this information by reference into previously filed S-8 registration statements.
When was this Form 6-K filed with the SEC?
This Form 6-K was filed with the SEC on April 8, 2025.
What does the '6-K' form signify?
A Form 6-K is a report of a foreign private issuer pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934.
Which previous filings are being updated by this 6-K?
This 6-K is incorporated by reference into the company's Registration Statements on Form S-8 filed on May 2, 2013, October 29, 2015, July 25, 2017, May 23, 2018, July 24, 2019, and March 25, 2021.
What is RedHill Biopharma Ltd.'s principal executive office address?
RedHill Biopharma Ltd.'s principal executive offices are located at 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on April 8, 2025 regarding RedHill Biopharma Ltd. (RDHL).